---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104164"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:57:21.591451+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics Q2 net loss $23.3M; cash runway into H2 2026; TN-201/401 data Q4 2025

## Summary
- Net loss $23.3M ($0.14 loss per share) vs $29.4M ($0.34) in Q2 2024.
- Cash, equivalents and marketable securities $71.7M as of June 30, 2025; runway into H2 2026.
- TN-201 for HCM: Cohorts 1 & 2 enrollment complete; DSMB allows expansion; data readout Q4 2025.
- TN-401 for ARVC: Cohort 1 enrolled; DSMB recommends dose escalation; first patient dosed in Cohort 2; data Q4 2025.
- R&D expense $17.4M vs $22.6M YoY; G&A $6.7M vs $8.2M YoY.

## SEC filing metadata
- accession: 0000950170-25-104164
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017025104164/0000950170-25-104164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017025104164/tnya-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104164
- JSON: https://secwatch.observer/filing/0000950170-25-104164.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.